These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 493374)
1. The "new drug" status of generic copies: a factor in drug product selection. Abood RR Pharm Manage Comb Am J Pharm; 1979; 151(4):160-3. PubMed ID: 493374 [No Abstract] [Full Text] [Related]
2. The Food and Drug Administration and patent law at a crossroads: the listing of polymorph patents as a barrier to generic drug entry. Srivastava D Food Drug Law J; 2004; 59(2):339-54. PubMed ID: 15298015 [No Abstract] [Full Text] [Related]
3. New York's generic drug substitution law. Kamen A N Y State Dent J; 1980 Nov; 46(9):599-604. PubMed ID: 6935574 [No Abstract] [Full Text] [Related]
4. Generic drug purchasing. Mehl B Hosp Pharm; 1988 Feb; 23(2):162-4 contd. PubMed ID: 10286432 [No Abstract] [Full Text] [Related]
5. Current issues in the pioneer versus generic drug wars. Safir PO Food Drug Law J; 1995; 50(2):335-9. PubMed ID: 10343002 [No Abstract] [Full Text] [Related]
7. FDA takes action against firms in scandal over generic products. Pollner F Med World News; 1989 Sep; 30(17):14-5. PubMed ID: 10294736 [No Abstract] [Full Text] [Related]
8. Generic vs. brand name drugs--quality, not cost, is key issue. Stetler CJ Internist; 1979 May; 20(4):9-10, 12. PubMed ID: 10242133 [No Abstract] [Full Text] [Related]
9. Benefits and liabilities of generic prescribing. Lee AM W V Med J; 1972 Jun; 68(6):161-6. PubMed ID: 4504384 [No Abstract] [Full Text] [Related]
11. Status of generic substitution: problematic drug classes reviewed. Ross MB Hosp Formul; 1989 Aug; 24(8):441-4, 447-9. PubMed ID: 10294356 [TBL] [Abstract][Full Text] [Related]
12. Generic vs. brand name drugs--defining and enforcing standards. Lasagna LC Internist; 1979 May; 20(4):11, 13. PubMed ID: 10316827 [No Abstract] [Full Text] [Related]
13. Substituting generic drugs: state roles. Cauchi R NCSL Legisbrief; 2009; 17(25):1-2. PubMed ID: 19526654 [No Abstract] [Full Text] [Related]
14. In U.S., biosimilars still await FDA decision. Finkelstein JB J Natl Cancer Inst; 2006 Apr; 98(7):435. PubMed ID: 16595775 [No Abstract] [Full Text] [Related]
15. FDA issues requirement for retaining drug samples. Oncology (Williston Park); 1991 May; 5(5):176. PubMed ID: 1832001 [No Abstract] [Full Text] [Related]
16. Generic warfarin: implications for clinical practice and perceptions of anticoagulation providers. Bongiorno RA; Nutescu EA Semin Thromb Hemost; 2004 Dec; 30(6):619-26. PubMed ID: 15630667 [TBL] [Abstract][Full Text] [Related]
17. Repercussions of the Drug Price Competition and Patent Term Restoration Act of 1984. Hogan GF Am J Hosp Pharm; 1985 Apr; 42(4):849-51. PubMed ID: 4014238 [TBL] [Abstract][Full Text] [Related]
18. Additional generics on the market. FDA Drug Bull; 1986 Nov; 16(2):14-5. PubMed ID: 3817341 [No Abstract] [Full Text] [Related]
20. Forces and direction of drug product selection legislation. Stewart JE Med Mark Media; 1979 Jun; 14(6):34-6, 38-9. PubMed ID: 10242281 [No Abstract] [Full Text] [Related] [Next] [New Search]